Condition: Advanced Solid Tumor · Hepatocellular Carcinoma · Sponsor: TORL Biotherapeutics, LLC
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
This description comes directly from the study's public registry record.
Caroline Labib, PharmD · 310-348-9636 · caroline.labib@torlbio.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Phoenix | Phoenix, Arizona, United States | Recruiting |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| UCLA - JCCC Clinical Research Unit | Los Angeles, California, United States | Recruiting |
| Torrance Memorial Physician Network | Torrance, California, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Florida Cancer Specialists Lake Nona Drug Development Unit | Orlando, Florida, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Virginia Cancer Specialists | Lexington, Virginia, United States | Recruiting |
| University Health Network, Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| McGill University Health Centre | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06005740